![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Praxis Precision Medicines Inc | NASDAQ:PRAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.17 | -0.30% | 56.78 | 51.99 | 60.46 | 57.41 | 55.00 | 55.10 | 261,254 | 23:17:14 |
|
Delaware
(State or other jurisdiction of
incorporation or organization) |
| |
47-5195942
(I.R.S. Employer
Identification Number) |
|
|
Peter N. Handrinos
Wesley C. Holmes Jennifer A. Yoon Latham & Watkins LLP 200 Clarendon Street Boston, Massachusetts 02116 (617) 880-4500 |
| |
Alex Nemiroff
General Counsel Praxis Precision Medicines, Inc. 99 High Street, 30th Floor Boston, MA 02110 (617) 300-8460 |
|
|
Large accelerated filer
☐
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☒
|
| |
Smaller reporting company
☒
|
|
| | | |
Emerging growth company
☐
|
|
| | | | | 1 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 13 | | | |
| | | | | 20 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 27 | | | |
| | | | | 29 | | | |
| | | | | 29 | | |
TABLE OF CONTENTS
|
| | | | | | |
| | |
Page
|
| |||
| | | | S-1 | | | |
| | | | S-3 | | | |
| | | | S-4 | | | |
| | | | S-5 | | | |
| | | | S-7 | | | |
| | | | S-9 | | | |
| | | | S-10 | | | |
| | | | S-12 | | | |
| | | | S-14 | | | |
| | | | S-14 | | | |
| | | | S-15 | | | |
| | | | S-16 | | |
|
Assumed public offering price per share
|
| | | | | | | | | $ | 4.64 | | |
|
Historical net tangible book value per share as of December 31, 2022
|
| | | $ | 1.54 | | | | | | | | |
|
Increase in net tangible book value per share attributable to new investors participating in this offering
|
| | | $ | 0.87 | | | | | | | | |
|
As adjusted net tangible book value per share as of December 31, 2022 after this offering
|
| | | | | | | | | $ | 2.41 | | |
|
Dilution per share to new investors participating in this offering
|
| | | | | | | | | $ | 2.23 | | |
|
SEC registration fee
|
| | | $ | 33,060 | | |
|
FINRA filing fee
|
| | | $ | 225,500 | | |
|
Printing expenses
|
| | | $ | (1) | | |
|
Legal fees and expenses
|
| | | $ | (1) | | |
|
Accounting fees and expenses
|
| | | $ | (1) | | |
|
Blue Sky, qualification fees and expenses
|
| | | $ | (1) | | |
|
Transfer agent fees and expenses
|
| | | $ | (1) | | |
|
Trustee fees and expenses
|
| | | $ | (1) | | |
|
Warrant agent fees and expenses
|
| | | $ | (1) | | |
|
Miscellaneous
|
| | | $ | (1) | | |
|
Total
|
| | | $ | (1) | | |
|
SIGNATURE
|
| |
TITLE
|
| |
DATE
|
|
|
/s/ Marcio Souza
Marcio Souza
|
| |
Chief Executive Officer and Director
(Principal Executive Officer) |
| | February 7, 2023 | |
|
/s/ Timothy Kelly
Timothy Kelly
|
| |
Chief Financial Officer
(Principal Financial Officer) |
| | February 7, 2023 | |
|
*
Lauren Mastrocola
|
| |
Principal Accounting Officer
|
| | February 7, 2023 | |
|
*
Dean Mitchell
|
| |
Chairman of the Board
|
| | February 7, 2023 | |
|
*
Jeffrey Chodakewitz, M.D.
|
| |
Director
|
| | February 7, 2023 | |
|
*
Merit Cudkowicz, M.D.
|
| |
Director
|
| | February 7, 2023 | |
|
/s/ Jill DeSimone
Jill DeSimone
|
| |
Director
|
| | February 7, 2023 | |
|
*
Gregory Norden
|
| |
Director
|
| | February 7, 2023 | |
|
*
William Young
|
| |
Director
|
| | February 7, 2023 | |
|
* By:
/s/ Marcio Souza
Marcio Souza
Attorney-in-Fact |
| | |
1 Year Praxis Precision Medicines Chart |
1 Month Praxis Precision Medicines Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions